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Introduction
Clinical diagnosis is integral to optimal patient care, 1 but in psychiatry the establishment of a clear diagnosis may be difficult. 2 One reason for this is the fact that many conditions can present with similar and overlapping symptoms. 3 Psychotic symptoms, notably hallucinations and delusions, are experienced in both affective and non-affective conditions, but differentiating between these subtypes in first-episode psychosis (FEP) patients is often problematic at presentation. 4 Although schizophrenia spectrum (SZ) and affective psychoses have different genetic risk factors, as well as distinct symptomatic profiles, 5 there remains no standard clinical test to differentiate these conditions. 6 Psychosocial risk factors have long been suggested to play an important role in the development of psychotic illness, 7-10 and it is possible that different risk factors might underlie affective and SZ psychoses, and that these could be used to improve diagnostic accuracy at first presentation in psychosis patients. This has the potential to significantly improve long-term management. 11 Most research to date on the association of psychosocial risk factors with psychosis has focused on SZ psychoses. [12] [13] [14] [15] There have, in addition, been several studies comparing psychosocial factors in SZ, manic (MP) and schizoaffective (SA) psychoses in FEP. [16] [17] [18] [19] [20] [21] [22] [23] [24] There are a relatively small number of studies examining psychosocial factors in FEP patients with depressive psychosis (DP). [25] [26] [27] [28] Interestingly, two of these studies found that there were more overlapping features between patients with depressive psychosis (DP) and SZ than with bipolar disorder. 27, 28 This contradicted the general assumption that patients with DP are often in the early stages of bipolar disorder. 29 These findings may enable clinicians to recognise and differentiate between MP, SZ and DP at an earlier stage, ultimately influencing future management and recovery. In this study, we aimed to test the hypothesis that different clinical diagnoses at 1 year in FEP patients taken on by Early Intervention in psychosis Services (EIS) in London were associated with distinct sociodemographic and clinical features at first presentation.
Methods
Data were drawn from MiData, a computerized audit tool based within Microsoft Access which was developed by the London Early Intervention Research Network. 30 Baseline measures were completed by clinicians based on their routine comprehensive assessments within 1 month of entry to EIS (baseline) and then 1 year later (follow-up). All clinicians were trained and were expected to reach at least 85% concordance with expert raters and other team members before being allowed to complete the measures on their patients. 30 The MiData database comprises a naturalistic cohort of referrals to seven inner-city EIS from Basic demographic data were obtained at baseline, including gender, age at entry to EIS, educational level, employment status, whether born in the UK, and ethnicity based on the 2001 UK national census categories. Participants were assessed for the presence or absence of: (i) family history of psychosis or any other mental illness in a first-degree relative; (ii) any incidents of violence towards others in their lifetime.
The degree of hostility in the preceding 2 weeks before presentation was assessed using the Brief Psychiatric Rating Scale. 31 This variable was quantitatively rated from 1 (none) to 7 (extremely severe). Substance use was measured with the combined alcohol use and drug use scale. 32 The lifetime use of Alcohol, Nicotine and Cannabis ('yes'/'no' for each) was recorded at presentation.
Duration of Untreated Psychosis (DUP) was assessed with a revised version of the
Nottingham Onset Schedule. 33 DUP was defined as: the number of days between the appearance of the first positive psychotic symptom (hallucination, delusion or thought disorder) and the date that antipsychotic medication was initiated and thereafter reported to have been taken for at least 75% of the subsequent month.
The Positive and Negative Syndrome Scale (PANSS) 34 was completed by clinicians at baseline to assess positive (PANSS-P) and negative (PANSS-N) psychotic symptoms. The Young Mania Rating Scale (YMRS) 35 was completed to assess manic symptoms. The Global Assessment of Functioning Scale disability subscale (GAF-d) 36 was also completed at baseline. ICD-10 (International Classification of Diseases-10) 37 diagnosis was recorded at 1-year follow up and was extracted from clinical records and confirmed with EIS consultant psychiatrists. These were grouped into schizophrenia-spectrum disorders (SZ) (ICD-10 codes F20-29), manic psychoses (MP) (F30.2, F31.2 or F31.5), depressive psychoses (DP) (F32.3, F33.3 or F39), and other disorders (OD) (all other codes).
Ethical Approval
Data were collected by each EIS in accordance with local audit procedures, which did not require patients to consent to collection of the data. Multi-centre ethical permission for secondary research use of anonymized versions of these datasets was provided by the Wandsworth Research Ethics Committee. HLF merged together the anonymized data supplied by each EIS following written consent from the team managers.
Missing Data
The supplementary tables reveal the distribution of missing data for each variable between the diagnostic categories. Any variable with greater than 50% missing data was not included in the subsequent analyses. Chi-square tests were performed to reveal any variables with statistically significant differences in missing data between the diagnostic subgroups; any such variables were also excluded from the subsequent analyses.
Data Analysis
The clinical diagnosis at follow-up remained the independent variable throughout. The subgroups were initially compared using standard baseline demographic variables: age, gender and ethnicity. Additional baseline variables were selected for further subgroup comparison. These variables were selected as they either a) presented significant results based on a preliminary comparison of all 148 baseline variables or b) were comparable factors used in prior studies comparing FEP patients with SZ, DP and MP. A final evaluation by Team was conducted to check for bias in the audit data collection.
Analysis for this paper was conducted using SPSS version 22 for Windows. Results are expressed as: mean (standard deviation) for continuous variables and as frequency n (%) for categorical variables. The p value was calculated for each dependent variable using standard procedures; statistical significance was set at p < 0.05. Histogram, box plots and QQ plots were used to assess for normality and outliers. For continuous variables, a oneway analysis of variance (ANOVA) test was used. The effect size was measured with the omega-squared measure (ѡ²), rather than eta-squared, to reduce bias. For categorical variables, the Pearson chi-square test for association (χ2) was used. The effect size for categorical variables (odds ratio) was not calculated as the contingency tables were always greater than 2 x 2. Post-hoc analysis using Tukey's honestly significant difference (HSD) test was performed on variables with statistically significant ANOVA values and a Bonferroni correction was used to account for multiple testing. Missing cases were automatically excluded by SPSS for each analysis.
Results
In total, 1014 patients in the MiData database had a diagnosis recorded at 1 year (92% of patients in database). Of these, 76% were categorised as SZ (N = 770), 9% as MP (N = 93), 6% as DP (N = 60) and 9% as OD (N = 91). As the heterogeneous nature of the OD subgroup would prevent any robust interpretation of the results, these patients were excluded to allow for a clearer comparison of the remaining three subgroups (N = 923). The majority of the remaining cohort was male (n = 598, 65%), and the mean age at presentation was 23 years old (SD = 4.7). The only significant difference between different EIS was that the Camden and Islington service had a lower proportion of SZ patients than the Wandsworth (ETHOS) and Hackney (EQUIP) services (Table 1 ).
There were significant differences between the diagnostic subgroups for age, gender and ethnicity at presentation ( Table 2) . Patients with a diagnosis at 1 year of MP were the youngest at presentation (mean [SD] = 22.4 [4.6]), with a greater proportion of female patients (46% male). SZ patients were predominantly male (68%) and DP patients were the oldest.
There were significant distinctions at presentation for a number of other variables. Level of hostility was higher in SZ than DP (p<0.05), although there was also a non-significant trend for hostility in MP to be higher than in DP (p<0.1). DUP was lower in MP than SZ or DP (p<0.05). Level of education was higher in MP than DP (p<0.05). SZ patients presented with a significantly higher incidence of violence in lifetime than DP patients (p<0.05).
The three diagnostic subgroups did not differ on country of birth, family history of psychosis or any mental illness, employment status, alcohol use, cannabis use and nicotine use ( Table   2) . Table 3 shows a breakdown of the clinical measures at baseline. There was a significant difference in baseline PANSS-P scores (F(2, 535) = 5.27, p = 0.005, ѡ = 0.13), PANSS negative scores (F(2, 514) = 6.73, p = 0.001, ѡ = 0.15) and YMRS scores (F(2, 532) = 24.24, p < 0.001, ѡ = 0.28) between diagnostic groups at 1 year. There were no significant baseline differences between the subgroups in GAF-d score.
Post-hoc analysis revealed that MP patients had a lower PANSS-N score (mean (SD) = 12.7 (5.55)) than SZ (mean (SD) = 17.0 (8.21), p = 0.001) and DP patients (mean (SD) = 17.3 (8.15), p = 0.019). They also had a greater YMRS score than DP and SZ patients (mean (SD) = 17.8 (14.04), both p's < 0.001), and a greater PANSS-P score (mean (SD) = 20.9 (8.86)) than DP patients (mean (SD) = 15.7 (5.31), p = 0.004).
Discussion
This is the largest study to date investigating the sociodemographic and clinical features of MP, DP and SZ patients at first presentation to EIS in London. A key proportion of patients were differentiated from SZ patients as MP (9%), DP (6%) and OD (9%) at 1 year. The proportion of patients with each diagnosis did not differ significantly between any of the EIS apart from Camden and Islington, most likely due to a difference in referral pattern or acceptance thresholds.
We found that MP patients differed most markedly from the SZ and DP subgroups, having shorter DUP, higher ratings on the YMRS, and lower negative symptoms (as measured by PANSS-N). The use of DUP as a measure of time should be interpreted with caution as it excludes any change in mood symptoms, which may present months before an acute manic episode. 38 Our finding that DP and SZ patients were more similar to each other than to MP patients is in keeping with earlier reports comparing psychosocial risk factors and psychopathology in FEP patients. 27, 28 It is important, however, to appreciate the potential limitations of using the PANSS to assess negative symptoms in patients with depression.
Confounding features shared between depression and negative symptoms diminish its specificity, especially as other key domains of negative symptomatology are absent. 39 Thus the relatively higher PANSS-N scores in the DP group in this study may have been due, at least in part, to depressive rather than negative symptoms.
In this study, the baseline demographics of each diagnostic subgroup were generally in keeping with previous reports: the majority of patients with SZ were black males of African origin; 3, 16, 18, 19, [23] [24] [25] [26] 28 MP patients were youngest at presentation but had achieved the highest level of education; 16, 18, 23, 26 MP patients had shorter DUP, and subsequently better outcomes. 25, 40, 41 The number of baseline variables producing a statistically significant difference involving all three diagnostic subgroups was limited. Furthermore, the calculated effect size of these differentiating variables was often small. These results underscore the multifaceted aetiology of these conditions and demonstrate the degree of overlap between the subgroups. In this study, SZ patients often occupied an intermediate level between DP and MP patients, and previous research has already proposed schizoaffective disorder as the intermediate between SZ and MP. 19, [22] [23] [24] These findings contribute to the ongoing discussion concerning the existence of a psychosis spectrum. 9, 14 The idea of the psychosis continuum has been developed as an alternative approach to categorical diagnosis in psychotic illness. It argues that the psychopathological profile at presentation is a better predictor of outcome than diagnostic subgroup, [42] [43] [44] and highlights a subset of the population with psychotic symptoms below the DSM criteria. 9 The diagnostic stability of the subgroups has also previously been questioned, 3 although a recent study reaffirmed the high diagnostic stability of SZ and affective psychoses. 45 Furthermore, patients with first-episode psychosis generally prefer to be told their diagnosis. 46 Nonetheless, it is worth remembering that future work will possibly redefine diagnostic categories in psychiatry based on underlying biological processes rather than superficial psychopathology. 47 Although this study illustrates the potential overlap in psychosocial variables, there were significant differences at presentation between the subgroups, supporting a more categorical distinction. 48 Ultimately, the critical objective is optimal treatment management. Studies have already illustrated the variable response to Lithium by SZ patients compared to bipolar patients. 49 Further evaluation of the diagnostic stability, reliability and prognostic value of the diagnostic subgroups is required to determine the best outcome of this debate.
Although this naturalistic study design contained a large cohort, and was therefore reasonably representative of the study population, there were a number of limitations which deserve attention. The first set of limitations relate to the collection of the primary data used.
The audit data was compiled by clinicians, not researchers. The current study centres around the clinical diagnosis at follow-up, however the factors employed to determine this outcome are largely unknown. For example, it would have also been interesting to note any changes to the preliminary working diagnosis. Additionally, the relatively small sample size of MP and DP patients warrants replication of these results using larger cohorts of patients with these diagnoses. Finally, the dataset contained a large amount of missing data; it is possible that a number of variables were not representative of the population. However, this bias was minimised as (i) the key demographics of the missing data did not vary from those of the whole cohort, (ii) no more than 50% of data was missing for any variable and (iii) there were no significant differences in missing data between the diagnostic subgroups. Missing data is common for audit data, especially in those of longitudinal design.
Conclusion
Patients presenting to EIS in London show distinct differences in both demographic variables and psychopathology at presentation between those who are eventually diagnosed with DP, MP and SZ. These findings may provide clinicians with supplementary tools to more accurately classify psychosis at initial presentation and design appropriate packages of care.
In particular, early and accurate diagnosis of DP patients is critical; this condition is often underreported and undertreated. 50 Further work to elucidate distinctions in the pathogenesis and aetiology of each disorder is vital to our understanding of these complex conditions.
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